Cargando…
Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of Na(V)1.7-Mediated Pain
Loss-of-function mutations of Na(V)1.7 lead to congenital insensitivity to pain, a rare condition resulting in individuals who are otherwise normal except for the inability to sense pain, making pharmacological inhibition of Na(V)1.7 a promising therapeutic strategy for the treatment of pain. We cha...
Autores principales: | Deuis, Jennifer R., Wingerd, Joshua S., Winter, Zoltan, Durek, Thomas, Dekan, Zoltan, Sousa, Silmara R., Zimmermann, Katharina, Hoffmann, Tali, Weidner, Christian, Nassar, Mohammed A., Alewood, Paul F., Lewis, Richard J., Vetter, Irina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810223/ https://www.ncbi.nlm.nih.gov/pubmed/26999206 http://dx.doi.org/10.3390/toxins8030078 |
Ejemplares similares
-
Addition of K22 Converts Spider Venom Peptide Pme2a from an Activator to an Inhibitor of Na(V)1.7
por: Yin, Kathleen, et al.
Publicado: (2020) -
Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia
por: Zakrzewska, Joanna M, et al.
Publicado: (2013) -
Discovery and mode of action of a novel analgesic β-toxin from the African spider Ceratogyrus darlingi
por: Sousa, Silmara R., et al.
Publicado: (2017) -
Pharmacological characterisation of the highly Na(V)1.7 selective spider venom peptide Pn3a
por: Deuis, Jennifer R., et al.
Publicado: (2017) -
Corrigendum: Pharmacological characterisation of the highly Na(V)1.7 selective spider venom peptide Pn3a
por: Deuis, Jennifer R., et al.
Publicado: (2017)